

Psoriasis Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

<https://marketpublishers.com/r/P9140A7347FBEN.html>

Date: August 2025

Pages: 90

Price: US\$ 3,200.00 (Single User License)

ID: P9140A7347FBEN

Abstracts

Psoriasis Treatment Drug Market Summary

Psoriasis is a chronic, immune-mediated inflammatory disease characterized primarily by red, scaly patches on the skin. It is not only a dermatological condition but also a systemic disease that may be associated with psoriatic arthritis and increased risks of cardiovascular, metabolic, and psychological comorbidities. Psoriasis treatment has evolved significantly over the past two decades, moving from traditional topical therapies and systemic drugs to highly targeted biologics and, more recently, oral small molecules that inhibit specific immune pathways. The global psoriasis treatment drug market has grown rapidly in line with advancements in immunology and biotechnology. By 2025, the market is estimated to reach USD 14–24 billion, supported by rising disease awareness, improved diagnostic practices, and the growing adoption of biologics and next-generation small molecule drugs. From 2025 to 2030, the market is expected to expand at a compound annual growth rate (CAGR) of 5.5%–8.5%, driven by robust uptake of biologics, expansion of pipeline assets, and broadening reimbursement coverage in developed economies.

Regional Market Trends

United States: The U.S. is the largest and most important market, accounting for more than 70% of global revenues. Several factors contribute to this dominance: high disease prevalence, rapid adoption of innovative biologics, premium drug pricing, and broad reimbursement. The U.S. market benefits from a strong presence of leading pharmaceutical companies, robust clinical trial infrastructure, and a supportive regulatory environment for innovative

immunology drugs. Growth in the U.S. is expected at a 6%–8% CAGR through 2030.

Europe: Western Europe represents the second-largest regional market, with significant revenues from Germany, the U.K., France, and Italy. National reimbursement policies and guideline-driven clinical practice support uptake of biologics, though cost containment measures can slow penetration of newer therapies. Growth is projected at a 5%–7% CAGR.

Asia-Pacific: Japan, South Korea, China, and India are showing rising demand as healthcare infrastructure improves and awareness of psoriasis as an immune-mediated systemic condition increases. Japan and South Korea are more advanced markets with established biologic adoption, while China and India are expected to contribute strong growth from a smaller base. Regional growth is estimated in the 6%–8.5% CAGR range.

Latin America: Brazil and Mexico lead adoption in Latin America, though market access challenges and limited insurance coverage restrict broad penetration of premium-priced biologics. Nevertheless, increasing access to generics and biosimilars supports steady growth, projected at 5%–6.5% CAGR.

Middle East & Africa: This region is the smallest but growing market, with increasing government spending on specialty pharmaceuticals and expansion of private insurance coverage. Growth is anticipated at 5%–6.5% CAGR, albeit from a limited base.

Product Type Segmentation and Trends

Risankizumab (Skyrizi; AbbVie): One of the fastest-growing therapies, risankizumab is an IL-23 inhibitor demonstrating strong efficacy and favorable dosing schedules. AbbVie reported USD 3,778 million in 2024 revenues for Skyrizi, making it a cornerstone of its immunology portfolio. Growth momentum remains strong, supported by continued uptake in plaque psoriasis and psoriatic arthritis, with expected growth in the 7%–8.5% CAGR range.

Guselkumab (Tremfya; Johnson & Johnson): Also targeting IL-23, guselkumab is a key biologic for Johnson & Johnson, generating USD 3,670 million in 2024. Its efficacy profile and competitive positioning against other IL-23 inhibitors

support ongoing growth at 6.5%–8% CAGR.

Ixekizumab (Taltz; Lilly): Ixekizumab, an IL-17A inhibitor, has established a strong presence in psoriasis and psoriatic arthritis. It is well-regarded for its rapid onset of action and broad efficacy across patient subgroups. Market growth is expected at 5.5%–7% CAGR.

Secukinumab (Cosentyx; Novartis): One of the first IL-17A inhibitors, secukinumab has become a blockbuster therapy with broad indications in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Though facing competitive pressures from newer biologics, it remains a leading therapy, projected to grow at 5%–6.5% CAGR.

Ustekinumab (Stelara; Janssen): An IL-12/23 inhibitor, ustekinumab is a well-established therapy but faces increasing competition from newer IL-23-specific inhibitors. While still widely used due to its broad immunology indications, growth is expected to slow to 3.5%–5% CAGR.

Deucravacitinib (Sotyktu; Bristol Myers Squibb): This TYK2 inhibitor is the first oral small molecule with a novel mechanism approved for psoriasis. Positioned as a highly effective oral therapy, it addresses patient preference for non-injectable options. Strong adoption is anticipated, with growth projected at 7%–8.5% CAGR, making it one of the fastest-growing therapies in the segment.

Apremilast (Otezla; Amgen): A PDE4 inhibitor, apremilast is the leading oral small molecule for psoriasis, though it is less effective than biologics. Amgen reported USD 2,126 million in 2024 revenues for Otezla. While competitive pressures from deucravacitinib are expected, Otezla remains relevant due to its oral administration and broad access. Growth is projected at 4%–5.5% CAGR.

Topical Products: Traditional therapies such as corticosteroids, vitamin D analogs, and combination products remain important for mild-to-moderate psoriasis, particularly in emerging markets. Growth is expected at a modest 2.5%–4% CAGR, given the increasing shift toward systemic and biologic therapies for moderate-to-severe disease.

Key Companies

AbbVie: A global biopharmaceutical leader, AbbVie dominates the psoriasis treatment drug market with Skyrizi and previously Humira. Skyrizi's strong sales trajectory reinforces AbbVie's leadership in immunology.

Johnson & Johnson (Janssen Pharmaceuticals): Janssen has long been a leader in immunology with Stelara and Tremfya, both of which are pivotal to its portfolio. Tremfya's rapid uptake underscores J&J's ability to adapt to evolving treatment paradigms.

Eli Lilly: Lilly's ixekizumab (Taltz) has gained strong traction in psoriasis and psoriatic arthritis, complementing its broader immunology and oncology pipelines.

Novartis: Novartis's Cosentyx was one of the earliest IL-17A inhibitors, and it continues to contribute significant revenues, maintaining a solid competitive position despite newer entrants.

Bristol Myers Squibb: BMS has expanded into dermatology with deucravacitinib, a differentiated TYK2 inhibitor that is poised to reshape the oral therapy segment in psoriasis.

Amgen: Amgen's Otezla remains a critical therapy, especially in patients preferring oral medications, though competition from deucravacitinib is expected to challenge future growth.

Porter's Five Forces Analysis

1. Threat of New Entrants – Low to Moderate

The psoriasis treatment drug market is characterized by high regulatory barriers, significant R&D investment requirements, and long development timelines. While biosimilars and generics may increase competition, barriers remain substantial for innovative therapies.

2. Bargaining Power of Suppliers – Moderate

Suppliers of biologics manufacturing technologies and raw materials for advanced therapies hold moderate power. However, major pharmaceutical companies often have

integrated capabilities, reducing dependency.

3. Bargaining Power of Buyers – High

Payers and healthcare systems exert strong bargaining power, particularly in Europe where cost-effectiveness assessments drive reimbursement. In the U.S., managed care organizations negotiate pricing, though market demand for effective therapies sustains pricing power for leading drugs.

4. Threat of Substitutes – Moderate

Substitution exists among biologics targeting different pathways (IL-23 vs. IL-17 vs. TYK2 inhibitors). However, given variability in patient response, multiple therapies coexist rather than replacing one another completely.

5. Industry Rivalry – High

Competition among AbbVie, J&J, Novartis, Lilly, Amgen, and BMS is intense. Each company competes for share in the moderate-to-severe psoriasis segment, with innovation, safety profiles, and dosing convenience being critical differentiators.

Opportunities and Challenges

Opportunities

Expansion of Oral Therapies: Patient demand for convenient, non-injectable options creates significant opportunities for oral agents like deucravacitinib.

Biologic Penetration in Emerging Markets: Rising healthcare infrastructure and expanding reimbursement in Asia-Pacific and Latin America open growth avenues for biologics.

Pipeline Innovation: Next-generation immunology drugs targeting novel pathways (e.g., IL-36, ROR γ inhibitors) may further expand treatment choices.

Comorbidity Management: Increased recognition of psoriasis as a systemic condition encourages comprehensive care, supporting greater uptake of advanced therapies.

Challenges

Pricing and Access Pressures: Payers increasingly scrutinize high-cost biologics, pushing for discounts, biosimilars, and cost-effectiveness evidence.

Biosimilar Competition: Patent expiries for established biologics such as ustekinumab will open the market to biosimilars, impacting branded revenues.

Safety Concerns: Long-term safety monitoring for new therapies remains critical, particularly for immunomodulators with potential systemic effects.

Market Saturation in Developed Regions: In the U.S. and Europe, biologic penetration is already high, limiting growth opportunities to patient switching and pipeline launches.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Psoriasis Treatment Drug Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST PSORIASIS TREATMENT DRUG MARKET IN NORTH AMERICA (2020-2030)

- 8.1 Psoriasis Treatment Drug Market Size
- 8.2 Psoriasis Treatment Drug Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Psoriasis Treatment Drug Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST PSORIASIS TREATMENT DRUG MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 Psoriasis Treatment Drug Market Size
- 9.2 Psoriasis Treatment Drug Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Psoriasis Treatment Drug Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina
 - 9.5.3 Chile
 - 9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST PSORIASIS TREATMENT DRUG MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 Psoriasis Treatment Drug Market Size
- 10.2 Psoriasis Treatment Drug Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Psoriasis Treatment Drug Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST PSORIASIS TREATMENT DRUG MARKET IN EUROPE (2020-2030)

- 11.1 Psoriasis Treatment Drug Market Size
- 11.2 Psoriasis Treatment Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Psoriasis Treatment Drug Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST PSORIASIS TREATMENT DRUG MARKET IN MEA (2020-2030)

- 12.1 Psoriasis Treatment Drug Market Size
- 12.2 Psoriasis Treatment Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Psoriasis Treatment Drug Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL PSORIASIS TREATMENT DRUG MARKET (2020-2025)

- 13.1 Psoriasis Treatment Drug Market Size
- 13.2 Psoriasis Treatment Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Psoriasis Treatment Drug Market Size by Type

CHAPTER 14 GLOBAL PSORIASIS TREATMENT DRUG MARKET FORECAST (2025-2030)

- 14.1 Psoriasis Treatment Drug Market Size Forecast
- 14.2 Psoriasis Treatment Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Psoriasis Treatment Drug Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 AbbVie
 - 15.1.1 Company Profile
 - 15.1.2 Main Business and Psoriasis Treatment Drug Information
 - 15.1.3 SWOT Analysis of AbbVie
 - 15.1.4 AbbVie Psoriasis Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Lilly
 - 15.2.1 Company Profile
 - 15.2.2 Main Business and Psoriasis Treatment Drug Information
 - 15.2.3 SWOT Analysis of Lilly
 - 15.2.4 Lilly Psoriasis Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Johnson & Johnson
 - 15.3.1 Company Profile
 - 15.3.2 Main Business and Psoriasis Treatment Drug Information
 - 15.3.3 SWOT Analysis of Johnson & Johnson
 - 15.3.4 Johnson & Johnson Psoriasis Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Novartis
 - 15.4.1 Company Profile
 - 15.4.2 Main Business and Psoriasis Treatment Drug Information
 - 15.4.3 SWOT Analysis of Novartis
 - 15.4.4 Novartis Psoriasis Treatment Drug Revenue, Gross Margin and Market Share

(2020-2025)

15.5 Bristol Myers Squibb

15.5.1 Company Profile

15.5.2 Main Business and Psoriasis Treatment Drug Information

15.5.3 SWOT Analysis of Bristol Myers Squibb

15.5.4 Bristol Myers Squibb Psoriasis Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.6 Amgen

15.6.1 Company Profile

15.6.2 Main Business and Psoriasis Treatment Drug Information

15.6.3 SWOT Analysis of Amgen

15.6.4 Amgen Psoriasis Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

- Table Abbreviation and Acronyms
- Table Research Scope of Psoriasis Treatment Drug Report
- Table Data Sources of Psoriasis Treatment Drug Report
- Table Major Assumptions of Psoriasis Treatment Drug Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Psoriasis Treatment Drug Picture
- Table Psoriasis Treatment Drug Classification
- Table Psoriasis Treatment Drug Applications
- Table Drivers of Psoriasis Treatment Drug Market
- Table Restraints of Psoriasis Treatment Drug Market
- Table Opportunities of Psoriasis Treatment Drug Market
- Table Threats of Psoriasis Treatment Drug Market
- Table Covid-19 Impact For Psoriasis Treatment Drug Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Psoriasis Treatment Drug
- Table Cost Structure Analysis of Psoriasis Treatment Drug
- Table Key End Users
- Table Latest News of Psoriasis Treatment Drug Market
- Table Merger and Acquisition
- Table Planned/Future Project of Psoriasis Treatment Drug Market
- Table Policy of Psoriasis Treatment Drug Market
- Table 2020-2030 North America Psoriasis Treatment Drug Market Size
- Figure 2020-2030 North America Psoriasis Treatment Drug Market Size and CAGR
- Table 2020-2030 North America Psoriasis Treatment Drug Market Size by Application
- Table 2020-2025 North America Psoriasis Treatment Drug Key Players Revenue
- Table 2020-2025 North America Psoriasis Treatment Drug Key Players Market Share
- Table 2020-2030 North America Psoriasis Treatment Drug Market Size by Type
- Table 2020-2030 United States Psoriasis Treatment Drug Market Size
- Table 2020-2030 Canada Psoriasis Treatment Drug Market Size
- Table 2020-2030 Mexico Psoriasis Treatment Drug Market Size
- Table 2020-2030 South America Psoriasis Treatment Drug Market Size
- Figure 2020-2030 South America Psoriasis Treatment Drug Market Size and CAGR
- Table 2020-2030 South America Psoriasis Treatment Drug Market Size by Application
- Table 2020-2025 South America Psoriasis Treatment Drug Key Players Revenue

Table 2020-2025 South America Psoriasis Treatment Drug Key Players Market Share
Table 2020-2030 South America Psoriasis Treatment Drug Market Size by Type
Table 2020-2030 Brazil Psoriasis Treatment Drug Market Size
Table 2020-2030 Argentina Psoriasis Treatment Drug Market Size
Table 2020-2030 Chile Psoriasis Treatment Drug Market Size
Table 2020-2030 Peru Psoriasis Treatment Drug Market Size
Table 2020-2030 Asia & Pacific Psoriasis Treatment Drug Market Size
Figure 2020-2030 Asia & Pacific Psoriasis Treatment Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Psoriasis Treatment Drug Market Size by Application
Table 2020-2025 Asia & Pacific Psoriasis Treatment Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Psoriasis Treatment Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Psoriasis Treatment Drug Market Size by Type
Table 2020-2030 China Psoriasis Treatment Drug Market Size
Table 2020-2030 India Psoriasis Treatment Drug Market Size
Table 2020-2030 Japan Psoriasis Treatment Drug Market Size
Table 2020-2030 South Korea Psoriasis Treatment Drug Market Size
Table 2020-2030 Southeast Asia Psoriasis Treatment Drug Market Size
Table 2020-2030 Australia Psoriasis Treatment Drug Market Size
Table 2020-2030 Europe Psoriasis Treatment Drug Market Size
Figure 2020-2030 Europe Psoriasis Treatment Drug Market Size and CAGR
Table 2020-2030 Europe Psoriasis Treatment Drug Market Size by Application
Table 2020-2025 Europe Psoriasis Treatment Drug Key Players Revenue
Table 2020-2025 Europe Psoriasis Treatment Drug Key Players Market Share
Table 2020-2030 Europe Psoriasis Treatment Drug Market Size by Type
Table 2020-2030 Germany Psoriasis Treatment Drug Market Size
Table 2020-2030 France Psoriasis Treatment Drug Market Size
Table 2020-2030 United Kingdom Psoriasis Treatment Drug Market Size
Table 2020-2030 Italy Psoriasis Treatment Drug Market Size
Table 2020-2030 Spain Psoriasis Treatment Drug Market Size
Table 2020-2030 Belgium Psoriasis Treatment Drug Market Size
Table 2020-2030 Netherlands Psoriasis Treatment Drug Market Size
Table 2020-2030 Austria Psoriasis Treatment Drug Market Size
Table 2020-2030 Poland Psoriasis Treatment Drug Market Size
Table 2020-2030 Russia Psoriasis Treatment Drug Market Size
Table 2020-2030 MEA Psoriasis Treatment Drug Market Size
Figure 2020-2030 MEA Psoriasis Treatment Drug Market Size and CAGR
Table 2020-2030 MEA Psoriasis Treatment Drug Market Size by Application
Table 2020-2025 MEA Psoriasis Treatment Drug Key Players Revenue
Table 2020-2025 MEA Psoriasis Treatment Drug Key Players Market Share

Table 2020-2030 MEA Psoriasis Treatment Drug Market Size by Type

Table 2020-2030 Egypt Psoriasis Treatment Drug Market Size

Table 2020-2030 Israel Psoriasis Treatment Drug Market Size

Table 2020-2030 South Africa Psoriasis Treatment Drug Market Size

Table 2020-2030 Gulf Cooperation Council Countries Psoriasis Treatment Drug Market Size

Table 2020-2030 Turkey Psoriasis Treatment Drug Market Size

Table 2020-2025 Global Psoriasis Treatment Drug Market Size by Region

Table 2020-2025 Global Psoriasis Treatment Drug Market Size Share by Region

Table 2020-2025 Global Psoriasis Treatment Drug Market Size by Application

Table 2020-2025 Global Psoriasis Treatment Drug Market Share by Application

Table 2020-2025 Global Psoriasis Treatment Drug Key Vendors Revenue

Figure 2020-2025 Global Psoriasis Treatment Drug Market Size and Growth Rate

Table 2020-2025 Global Psoriasis Treatment Drug Key Vendors Market Share

Table 2020-2025 Global Psoriasis Treatment Drug Market Size by Type

Table 2020-2025 Global Psoriasis Treatment Drug Market Share by Type

Table 2025-2030 Global Psoriasis Treatment Drug Market Size by Region

Table 2025-2030 Global Psoriasis Treatment Drug Market Size Share by Region

Table 2025-2030 Global Psoriasis Treatment Drug Market Size by Application

Table 2025-2030 Global Psoriasis Treatment Drug Market Share by Application

Table 2025-2030 Global Psoriasis Treatment Drug Key Vendors Revenue

Figure 2025-2030 Global Psoriasis Treatment Drug Market Size and Growth Rate

Table 2025-2030 Global Psoriasis Treatment Drug Key Vendors Market Share

Table 2025-2030 Global Psoriasis Treatment Drug Market Size by Type

Table 2025-2030 Psoriasis Treatment Drug Global Market Share by Type

I would like to order

Product name: Psoriasis Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Product link: <https://marketpublishers.com/r/P9140A7347FBEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9140A7347FBEN.html>